The European Union's drugs regulator has rejected Eisai and Biogen's Leqembi treatment for early Alzheimer's disease, saying the risk of serious brain swelling did...
A charity will pay $4 million to resolve claims that it acted as a conduit for companies including Biogen and Novartis to pay kickbacks to patients using their high-priced multiple sclerosis drugs